Group 1 - A class action has been filed on behalf of shareholders of Alto Neuroscience, Inc. (NYSE: ANRO) [1] - The class action pertains to purchases of common stock made during Alto's initial public offering on or about February 2, 2024, and securities purchased between February 2, 2024, and October 22, 2024 [1] - Alto Neuroscience is identified as a clinical-stage biopharmaceutical company based in the U.S. [1]

Core Viewpoint - Rosen Law Firm is reminding investors who purchased common stock of Alto Neuroscience, Inc. about a class action lawsuit related to misleading statements made during the company's IPO and subsequent period [1][5]. Group 1: Class Action Details - The class action pertains to investors who purchased Alto securities during the IPO on February 2, 2024, and up until October 22, 2024 [1]. - A lead plaintiff deadline has been set for September 19, 2025, for those wishing to represent the class [1][3]. Group 2: Compensation Information - Investors may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. Group 3: Allegations Against Alto Neuroscience - The lawsuit claims that Alto made materially false and misleading statements regarding its product ALTO-100, particularly its effectiveness in treating major depressive disorder (MDD) [5]. - It is alleged that the clinical, regulatory, and commercial prospects of ALTO-100 were overstated, leading to inflated business and financial prospects for Alto [5].

Core Viewpoint - A class action securities lawsuit has been filed against Alto Neuroscience, Inc. due to alleged securities fraud affecting investors who purchased shares during the company's initial public offering and subsequent period [1][2]. Group 1: Lawsuit Details - The lawsuit aims to recover losses for investors who acquired Alto common stock linked to the Offering Documents from the IPO on February 2, 2024, and securities purchased between February 2, 2024, and October 22, 2024 [2]. - The complaint alleges that the company made false statements regarding the effectiveness of its product pipeline, ALTO-100, in treating major depressive disorder, overstating its clinical, regulatory, and commercial prospects [3]. Group 2: Next Steps for Investors - Investors who suffered losses during the specified timeframe have until September 19, 2025, to request appointment as lead plaintiff, although participation in any recovery does not require serving in this role [4]. - Class members may be entitled to compensation without any out-of-pocket costs or fees [4]. Group 3: Firm Background - Levi & Korsinsky, LLP has a history of securing significant settlements for shareholders and is recognized as one of the top securities litigation firms in the United States [5].

Core Viewpoint - A class action securities lawsuit has been filed against Alto Neuroscience, Inc. due to alleged securities fraud affecting investors who purchased shares during the company's initial public offering and subsequent period [1][2]. Group 1: Lawsuit Details - The lawsuit aims to recover losses for investors who acquired Alto common stock related to the initial public offering on February 2, 2024, and securities purchased between February 2, 2024, and October 22, 2024 [2]. - The complaint alleges that the defendants made false statements regarding the effectiveness of the product pipeline, ALTO-100, in treating major depressive disorder, overstating its clinical, regulatory, and commercial prospects [3]. Group 2: Next Steps for Investors - Investors who suffered losses during the relevant timeframe have until September 19, 2025, to request appointment as lead plaintiff, although participation in any recovery does not require serving as lead plaintiff [4]. - Class members may be entitled to compensation without any out-of-pocket costs or fees [4]. Group 3: Firm Background - Levi & Korsinsky has a history of securing hundreds of millions of dollars for shareholders and is recognized as one of the top securities litigation firms in the United States [5].

Core Viewpoint - A class action lawsuit has been filed against Alto Neuroscience, Inc. for allegedly misleading investors regarding the effectiveness of its drug ALTO-100 during the class period from February 2, 2024, to October 22, 2024 [2][3]. Group 1: Lawsuit Details - The lawsuit is on behalf of all individuals and entities who purchased Alto securities during the specified class period [2]. - Investors have until September 19, 2025, to apply to the Court to be appointed as lead plaintiff in the lawsuit [2]. - The complaint alleges that the Offering Documents for the IPO were negligently prepared and that key information about ALTO-100's effectiveness was not disclosed [3]. Group 2: Impact on Stock Price - On October 22, 2024, Alto announced that ALTO-100 did not meet its primary endpoint in a Phase 2b trial for treating Major Depressive Disorder (MDD), leading to a significant stock price drop [4]. - Following the announcement, Alto's stock price fell by $10.17 per share, or 69.99%, closing at $4.36 per share on October 23, 2024 [4]. Group 3: Contact Information - Investors who suffered losses or have questions regarding the lawsuit can contact Bragar Eagel & Squire, P.C. for more information [5][8].

NEW YORK, Sept. 09, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Alto Neuroscience, Inc. (NYSE: ANRO): (i) pursuant and/or traceable to Alto’s initial public offering conducted on or about February 2, 2024 (the “IPO”); and/or (ii) securities between February 2, 2024 and October 22, 2024, both dates inclusive (the “Class Period”), of the important September 19, 2025 lead plaintiff deadline. SO WHAT: If you purchased Alto securities yo ...

Alto Neuroscience (NYSE:ANRO) FY Conference September 09, 2025 02:00 PM ET Company ParticipantsAmit Etkin - CEOConference Call ParticipantsPatrick Trucchio - Biotechnology AnalystPatrick TrucchioGood afternoon, everyone. Welcome back to the H.C. Wainwright 27th Annual Global Investment Conference on September 8 to September 10, 2025. I'm Patrick Trucchio, a Senior Healthcare Analyst at HC Wainwright. It's my pleasure to introduce our next company, Alto Neuroscience, a clinical-stage biopharmaceutical compan ...

What to do next: To join the Alto class action, go to https://rosenlegal.com/submit-form/?case_id=42321 or call Phillip Kim, Esq. at 866-767-3653 or email [email protected] for more information. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than September 19, 2025. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. Why Rosen Law: We encourage investors to select qualified ...

"Company†) (NYSE: ANRO). Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm has recovered hundreds of millions of dollars for investors since its founding in 1995. See www.faruqilaw.com. On October 22, 2024, Alto issued a press release annou. NEW YORK--(BUSINESS WIRE)---- $ANRO #ANRO--Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Alto Neuroscience, Inc. ("Alto†or the ...

MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)---- $ANRO #biomarkers--Alto Neuroscience, Inc. ("Alto†) (NYSE: ANRO) a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today announced positive results from an independent, prospective replication study evaluating electroencephalography (EEG) biomarkers in people with schizophrenia. The study successfully replicated previous findings, demonstrating that event-related theta-band responses ...